Skip to main content

Table 2 Proportions of underlying biomedical and demographic characteristics and unadjusted hazard ratios among cART recipients attending two HIV clinics in Gaborone, Botswana. Status variable: Diabetes mellitus-related comorbidities (DRCs, N = 531)

From: Relationship between combination antiretroviral therapy regimens and diabetes mellitus-related comorbidities among HIV patients in Gaborone Botswana

Covariates Proportion Number (%) Unadjusted
HR 95%CI P value
Male 163 (30.7) 0.58 0.38–0.89 0.012
Age ± SE 41.39 ± 0.38 1.03 1.01–1.05 0.006
≤35 years old 132 (24.9) 0.40 0.20–0.80 0.01
CD4–1 ≤ 200 cells/mm3 124 (23.4) 1.6 1.03–2.6 0.036
CD4–1 ≥ 350 cells/mm3 24 (4.5) 0.99 0.31–3.16 0–90
CD4–2 ≤ 200 cells/mm3 34 (6.4) 0.94 0.38–2.32 0.89
CD4–2 ≥ 350 cells/mm3 420 (79.1) 1,16 0.67–2.04 0.58
PMH Clinic 314 (50.1) 6.41 3.55–11.56 0.001
Adherence
No 31 (5.8) 1
Yes 478 (90.0) 4.53 1.42–14.47 0.01
Unknown 22 (4.1) 1.14 0.41–3.12 0.79
1Switched cART Line
Did not switch 235 (44.3) 1
From cART line1 to line 2 281 (52.9) 0.75 0.49–1.15 0.18
Unknown 15 (2.8) 1.28 0.46–3.58 0.63
BMI at cART
Normal weight 337 (63.5) 1
Underweight 80 (15.1) 0.88 0.46–1.69 0.71
Overweight 114 (21.4) 1.63 1.02–2.61 0.043
  1. HR = Hazard ratio, CI = confidence interval, 1Switched cART regimens = switched from the initial cART line to another line, Unknown = whether the patient switched regimen or not is unclear, BMI at cART = BMI at initiation on cART, CD4–1 cells/mm3 = CD4 count at initiation on cART, CD4–2 cells/mm3 = CD4 count after initiation on cART